Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTZBXQ)

Drug Name

GSK-159797 Drug Info

Synonyms

Milveterol hydrochloride; UNII-1D1MD355SJ; 1D1MD355SJ; 804518-03-4; Milveterol hydrochloride [USAN]; Milveterol hydrochloride (USAN); GSK159797C; Milveterol HCl; SCHEMBL2014099; CHEMBL2107356; DTXSID50230335; QQPHRRSYJMOQOC-DKIIUIKKSA-N; D08945; N-{2-[4-((R)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(R)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine; 2-5A-anti-hTR

Indication

Disease Entry	ICD 11	Status	REF
Chronic obstructive pulmonary disease	CA22	Discontinued in Phase 2	[1]

Cross-matching ID

PubChem CID: 11225217
CAS Number: CAS 804518-03-4
TTD Drug ID: DMTZBXQ

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Adrenergic receptor beta-2 (ADRB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indacaterol	DMQJHR7	Chronic obstructive pulmonary disease	CA22	Approved	[3]
Formoterol	DMSOURV	Allergic asthma	CA23.0	Approved	[4]
Salbutamol	DMN9CWF	Acute asthma	CA23	Approved	[5]
Arformoterol	DMYM974	Chronic obstructive pulmonary disease	CA22	Approved	[6]
Isoproterenol	DMK7MEY	Atrioventricular block		Approved	[7]
Salmeterol	DMIEU69	Allergic asthma	CA23.0	Approved	[8]
Clenbuterol	DMCKYZ5	Chronic breathing disorder	7A4Z	Approved	[9]
Ritodrine	DM4V6RL	Premature labour	JB00	Approved	[10]
Olodaterol	DM62B78	Chronic obstructive pulmonary disease	CA22	Approved	[11]
Fenoterol	DMIP3ZV	Asthma	CA23	Approved	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor beta-2 (ADRB2)	TT2CJVK	ADRB2_HUMAN	Agonist	[1]
Telomerase messenger RNA (Telomerase mRNA)	TTDW3Z2	NOUNIPROTAC	Not Available	[2]

------------------------------------------------------------------------------------

References

1	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
2	Combination therapy of 2-5A antisense against telomerase RNA and cisplatin for malignant gliomas. Int J Oncol. 2001 Jun;18(6):1287-92.
3	Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94.
4	Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst Rev. 2002;(3):CD001104.
5	Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol). CNS Drugs. 2002;16(1):1-8.
6	Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. Drugs Today (Barc). 2009 Jan;45(1):3-9.
7	Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
8	Pharmacogenetic tests in asthma therapy. Clin Lab Med. 2008 Dec;28(4):645-65.
9	Postischemic brain injury is attenuated in mice lacking the beta2-adrenergic receptor. Anesth Analg. 2009 Jan;108(1):280-7.
10	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
11	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
12	Functional alpha1- and beta2-adrenergic receptors in human osteoblasts. J Cell Physiol. 2009 Jul;220(1):267-75.